TerraPlant
Through a proprietary process, we can produce small molecules and proteins.
The focus of our first initiative will be rare cannabinoids and terpenes to establish ourselves in the $100 billion emerging market.
Our process can also be used to produce vaccines, insulin, vitamins, biofuels, opioids and protein supplements.
Very excited to announce our new partnership with the Loyalist College Centre for Natural Products and Medical Cannabis to develop our proof of concept, with funding provided by the GreenCentre Canada CONNECT program. This will allow us to validate the prototype and minimum viable product for our system.
Our technology is a "game changer" as it is the first to be completely compatible with the existing cannabis infrastructure, allowing companies to enter the multi-billion dollar rare cannabinoid and terpene markets at no extra cost.
Interested in learning more?
We invite dialogue with the cannabis industry, colleagues in the biotech sector, academic research groups, passionate entrepreneurs and investment professionals.